

(86) 1999/05/21

(87) 1999/12/02

(72) SIRCAR, JAGADISH, US

(72) RICHARDS, MARK L., US

(72) CAMPBELL, MICHAEL G., US

(72) MAJOR, MICHAEL W., US

(71) AVANIR PHARMACEUTICALS, US

(51) Int.Cl.⁶ A61K 31/335, A61K 31/535, A61K 31/445, A61K 31/42,
A61K 31/40, A61K 31/395, A61K 31/18, A61K 31/165,
A61K 31/135

(30) 1998/05/22 (60/086,494) US

(54) **COMPOSES AYANT DES PROPRIETES AFFECTANT LES IGE**

(54) **COMPOUNDS HAVING IGE AFFECTING PROPERTIES**

(57) La présente invention se rapporte à de petites molécules inhibitrices de la réponse des IgE aux allergènes, qui sont utiles pour le traitement des allergies et/ou de l'asthme ou de toute maladie où le taux d'IgE est pathogène.

(57) The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00	A2	(11) International Publication Number: WO 99/61013 (43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11363 (22) International Filing Date: 21 May 1999 (21.05.99) (30) Priority Data: 60/086,494 22 May 1998 (22.05.98) US (71) Applicant: AVANIR PHARMACEUTICALS [US/US]; 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). (72) Inventors: SIRCAR, Jagadish; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). RICHARDS, Mark, L.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). CAMPBELL, Michael, G.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). MAJOR, Michael, W.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). (74) Agent: ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).		(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: COMPOUNDS HAVING IgE AFFECTING PROPERTIES		
(57) Abstract <p>The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.</p>		

COMPOUNDS HAVING IgE AFFECTING PROPERTIES

Background of the Invention

This invention relates to small molecule inhibitors of the IgE response to allergens that are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

5 An estimated 10 million persons in the United States have asthma, about 5% of the population. The estimated cost of asthma in the United States exceeds \$6 billion. About 25% of patients with asthma who seek emergency care require hospitalization, and the largest single direct medical expenditure for asthma has been inpatient hospital services (emergency care), at a cost of greater than \$1.6 billion. The cost for prescription medications, which increased 54% between 1985 and 1990, was close behind at \$1.1 billion (Kelly, *Pharmacotherapy* 12:13S-21S (1997)).

10 According to the National Ambulatory Medical Care Survey, asthma accounts for 1% of all ambulatory care visits, and the disease continues to be a significant cause of missed school days in children. Despite improved understanding of the disease process and better drugs, asthma morbidity and mortality continue to rise in this country and worldwide (U.S. Department of Health and Human Services; 1991, publication no. 91-3042). Thus, asthma constitutes a significant public health problem.

20 The pathophysiologic processes that attend the onset of an asthmatic episode can be broken down into essentially two phases, both marked by bronchoconstriction, that causes wheezing, chest tightness, and dyspnea. The first, early phase asthmatic response is triggered by allergens, irritants, or exercise. Allergens cross-link immunoglobulin E (IgE) molecules bound to receptors on mast cells, causing them to release a number of pre-formed inflammatory mediators, including histamine. Additional triggers include the osmotic changes in airway tissues following exercise or the inhalation of cold, dry air.

25 The second, late phase response that follows is characterized by infiltration of activated eosinophils and other inflammatory cells into airway tissues, epithelial desquamation, and by the presence of highly viscous mucus within the airways. The damage caused by this

WO 99/61013

PCT/US99/11363

inflammatory response leaves the airways "primed" or sensitized, such that smaller triggers are required to elicit subsequent asthma symptoms.

A number of drugs are available for the palliative treatment of asthma; however, their efficacies vary markedly. Short-acting β_2 -adrenergic agonists, terbutaline and albuterol, long the mainstay of asthma treatment, act primarily during the early phase as bronchodilators. The newer long-acting β_2 -agonists, salmeterol and formoterol, may reduce the bronchoconstrictive component of the late response. However, because the β_2 -agonists do not possess significant antiinflammatory activity, they have no effect on bronchial hyperreactivity.

Numerous other drugs target specific aspects of the early or late asthmatic responses. For example, antihistamines, like loratadine, inhibit early histamine-mediated inflammatory responses. Some of the newer antihistamines, such as azelastine and ketotifen, may have both antiinflammatory and weak bronchodilatory effects, but they currently do not have any established efficacy in asthma treatment. Phosphodiesterase inhibitors, like theophylline/xanthines, may attenuate late inflammatory responses, but there is no evidence that these compounds decrease bronchial hyperreactivity. Anticholinergics, like ipratropium bromide, which are used in cases of acute asthma to inhibit severe bronchoconstriction, have no effect on early or late phase inflammation, no effect on bronchial hyperreactivity, and therefore, essentially no role in chronic therapy.

The corticosteroid drugs, like budesonide, are the most potent antiinflammatory agents. Inflammatory mediator release inhibitors, like cromolyn and nedocromil, act by stabilizing mast cells and thereby inhibiting the late phase inflammatory response to allergen. Thus, cromolyn and nedocromil, as well as the corticosteroids, all reduce bronchial hyperreactivity by minimizing the sensitizing effect of inflammatory damage to the airways. Unfortunately, these antiinflammatory agents do not produce bronchodilation.

Several new agents have been developed that inhibit specific aspects of asthmatic inflammation. For instance, leukotriene receptor antagonists (ICI-204, 219, accolate), specifically inhibit leukotriene-mediated actions. The leukotrienes have been implicated in the production of both airway inflammation and bronchoconstriction.

WO 99/61013

PCT/US99/11363

Thus, while numerous drugs are currently available for the treatment of asthma, these compounds are primarily palliative and/or have significant side effects. Consequently, new therapeutic approaches which target the underlying cause rather than the cascade of symptoms would be highly desirable. Asthma and allergy share a common
5 dependence on IgE-mediated events. Indeed, it is known that excess IgE production is the underlying cause of allergies in general and allergic asthma in particular (Duplantier and Cheng, *Ann. Rep. Med. Chem.* 29:73-81 (1994)). Thus, compounds that lower IgE levels may be effective in treating the underlying cause of asthma and allergy.

None of the current therapies eliminate the excess circulating IgE. The
10 hypothesis that lowering plasma IgE may reduce the allergic response, was confirmed by recent clinical results with chimeric anti-IgE antibody, CGP-51901, and recombinant humanized monoclonal antibody, rhuMAB-E25. Indeed, three companies, Tanox Biosystems, Inc., Genentech Inc. and Novartis AG are collaborating in the development of a humanized anti-IgE antibody (BioWorld® Today, February 26, 1997, p. 2) which
15 will treat allergy and asthma by neutralizing excess IgE. Tanox has already successfully tested the anti-IgE antibody, CGP-51901, which reduced the severity and duration of nasal symptoms of allergic rhinitis in a 155-patient Phase II trial (Scrip #2080, Nov 24, 1995, p.26). Genentech recently disclosed positive results from a 536 patient phase-II/III trials of its recombinant humanized monoclonal antibody, rhuMAB-E25
20 (BioWorld® Today, November 10, 1998, p. 1). The antibody, rhuMAB-E25, administered by injection (highest dose 300 mg every 2 to 4 weeks as needed) provided a 50% reduction in the number of days a patient required additional "rescue" medicines (antihistamines and decongestants), compared to placebo. An NDA filing for this product is projected to be in the year 2000. The positive results from anti-IgE antibody
25 trials suggest that therapeutic strategies aimed at IgE down-regulation may be effective.


Summary of the Invention

The present invention discloses several compounds that are active in down-regulating the IgE response to allergens and other provocative stimuli. One compound is

WO 99/61013


PCT/US99/11363

disclosed for use in the treatment of a condition associated with an excess IgE level. The compound has a formula:



wherein n is 1 to 3 and wherein R is H, alkyl, aryl, aminoalkyl, alkylaminoalkyl, substituted aryl or hydroxyalkyl. X , Y and Z are selected independently from the group consisting of H, alkoxy, aryloxy, alkyl, aryl, heteroaryl, hydroxyalkyl, carboxy, amine, alkylamino, cycloalkylamine, morpholine, thiomorpholine, alkoxycarbonyl, hydroxy, cyano, sulfonamide, alkylsulfonamide, substituted aryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, nitro, halogen, thioalkyl, sulfoxyalkyl and sulfonylalkyl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein X and Y are independently selected from the group consisting of H, alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, benzyl, aryl, heteroaryl, hydroxy, carboxy, halogen, trifluoromethyl, trifluoromethoxy, carboxyalkyl, nitro, cyano, alkylsulfonyl, sulfonamide, alkylsulfonamides, amino, alkylamino, morpholine, thiomorpholine, alkylthio, sulfoxyalkyl and sulfonylalkyl. R_1 and R_2 are independently selected from the group consisting of H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl. R_3 is selected from the group consisting of H, alkyl, aryl, CO-alkyl, CO-aryl and CO-heteroaryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:


WO 99/61013

PCT/US99/11363




wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl. R_3 is selected from the group consisting of H, alkyl, aryl, CO-alkyl, CO-aryl, dialkylaminoalkyl, dialkylaminoalkylcarbonyl, substituted aryl, substituted heteroaryl and CO-heteroaryl, and R is selected from the group consisting of H, aryl, heteroaryl, substituted aryl and substituted heteroaryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



wherein X and Y are independently H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino or alkylamino. R , R' , R'' and R''' are independently H, alkyl, alkoxyalkyl or dialkylaminoalkyl, and R'' and R''' may independently also be a halogen.

A preferred variation on the cyclopropyl-substituted compound above is illustrated by the formula:




wherein Z is H_2 or O. X and Y are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted

WO 99/61013

PCT/US99/11363


heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and alkylamino. R_1 and R_2 may be selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

- 5 A related compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



- 10 wherein Z is H_2 or O. X and Y are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and alkylamino. R_1 and R_2 are selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

- 15 Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




- 20 wherein X and Y are selected independently from the group consisting of H, halogens, alkyl, alkoxy, aryl, amino, alkylamino, cycloalkylamino, morpholine, thiomorpholine,

WO 99/61013

PCT/US99/11363


hydroxy, cyano, nitro, carboxy, alkoxycarbonyl, trifluoromethyl and trifluoromethoxy. R, R', R'' and R''' are selected independently from the group consisting of H, alkyl, aryl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, heteroaryl, arylalkyl, dialkylaminoalkyl and hydroxyalkyl.

- 5 Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



- 10 wherein R is selected from the group consisting of aliphatic, aromatic, heterocyclic, substituted aromatic and substituted heterocyclic. X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, nitro, trifluoromethyl, trifluoromethoxy and cyano.

- 15 Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein R₁ is selected from the group consisting of H, halogen, alkoxy, alkyl, nitro, cyano, amino, CF₃, OCF₃ and hydroxy. R₂ is selected from the group consisting of H, alkyl and aminoalkyl, R₃ is H or alkyl, and R₄ and R₅ are independently selected from

WO 99/61013

PCT/US99/11363


the group consisting of H, alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, cycloalkyl, aryl, aminocycloalkyl, hydroxyalkyl and substituted aryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



wherein R and R' are selected independently from the group consisting of H, methyl, alkyl, aryl and substituted aryl. X, Y and Z are independently selected from the group consisting of H, halogen, alkyl, alkoxy, benzo, fused heterocyclic, CF₃, OCF₃, CN, COOH and COOR".

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein the heterocyclic ring is selected from the group consisting of pyridines, quinolines, substituted pyridines and substituted quinolines. R and R' are independently selected from the group consisting of H, methyl, alkyl, aryl and substituted aryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:


WO 99/61013

PCT/US99/11363



wherein X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF₃ and OCF₃. R is selected from the group consisting of H, CH₃, C₂H₅, C₃H₇ and C₄H₉, and R₁ and R₂ are selected independently from the group consisting of H, methyl, ethyl, butyl, benzyl, substituted benzyl, dialkylaminoalkyl, alkyl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, substituted fused cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein X and Y are selected independently from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, halogen, NO₂, CF₃, OCF₃, NH₂, NHR₃, NR₃R₄ and CN. Z is O, S, NH, and N-R'. R is selected from the group consisting of H, alkyl, halogen, alkoxy, CF₃ and OCF₃. R' is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl, and R₁ and R₂ are independently selected from the group consisting of H, alkyl, aminoalkyl,

WO 99/61013

PCT/US99/11363


dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



wherein R_1 and R_2 are selected independently from the group consisting of H, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl. X is selected from the group consisting of H, halogen, alkoxy, alkyl, CF_3 , NO_2 , CN and OCF_3 . R_3 and R_4 are selected independently from the group consisting of H, alkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




where R_1 , R_2 , R_3 , R_4 , R_5 and R_6 are selected independently from the group consisting of H, alkyl, cycloalkyl, oxacycloalkyl, thiocycloalkyl, aryl, arylalkyl, heteroaryl, heteroalkyl, substituted aryl and substituted heteroaryl.

WO 99/61013

PCT/US99/11363

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



- 5 wherein R_1 and R_2 are independently selected from the group consisting of H, alkyl, aryl, alkylaryl, substituted alkyl, substituted arylalkyl, dialkyl and aminoalkyl. R_3 is selected from the group consisting of H, alkyl, aryl, halogen, CF_3 , OCF_3 , CN, NO_2 , NH_2 , NHR, carboxy, carboxyalkyl, alkoxy, heteroaryl, fused aryl and fused heteroaryl.

- 10 A method for treating a disease condition associated with excess IgE in a mammal is disclosed. The method comprises the step of administering to the mammal an IgE-suppressing amount of a pharmaceutical formulation comprising at least one IgE-suppressing compound from the above-disclosed small molecule families. In accordance with a variation of the method of treatment, the small molecule IgE-suppressing compound may be administered in conjunction with at least one additional agent, which is
- 15 active in reducing a symptom associated with an allergic reaction. In one embodiment, the small molecule inhibitor may be mixed with at least one additional active ingredient to form a pharmaceutical composition. Alternatively, the small molecule inhibitor may be co-administered at the same time or according to different treatment regimens with the at least one additional active agent.

- 20 The at least one additional active ingredient may be a short-acting β_2 -adrenergic agonist selected from the group consisting of terbutaline and albuterol; a long-acting β_2 -adrenergic agonist selected from the group consisting of salmeterol and formoterol; an antihistamine selected from the group consisting of loratadine, azelastine and ketotifen; a





WO 99/61013

PCT/US99/11363

phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor or a leukotriene receptor antagonist.






A dose of about 0.01 mg to about 100 mg per kg body weight per day of the small molecule IgE inhibitory compound is preferably administered in divided doses for at least two consecutive days at regular periodic intervals.

A method for treating a disease condition associated with excess IgE in a mammal is also disclosed which comprises the step of administering to the mammal an IgE-suppressing amount of a pharmaceutical formulation comprising at least one compound selected from the following group of compounds:







WO 99/61013

PCT/US99/11363






WO 99/61013

PCT/US99/11363








WO 99/61013

PCT/US99/11363







WO 99/61013

PCT/US99/11363







WO 99/61013

PCT/US99/11363





WO 99/61013

PCT/US99/11363



WO 99/61013

PCT/US99/11363



wherein Z is selected from the group consisting of NH, O, S and N-R';

wherein R' is selected from the group consisting of H, alkyl, aminoalkyl,

5 and dialkylaminoalkyl;


wherein R₁ is selected from the group consisting of H, Cl and


SO₂CH₂CH₃; and

wherein R₂ is selected from the group consisting of H, Cl, CH₃, OCH₃,

COOH and CF₃,

10





5

Other variations within the scope of the present invention may be more fully understood with reference to the following detailed description.

Detailed Description of the Preferred Embodiment

10

The present invention is directed to small molecule inhibitors of IgE (synthesis and/or release) which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The particular compounds disclosed herein were identified by

WO 99/61013

PCT/US99/11363

their ability to suppress IgE levels in both *ex vivo* and *in vivo* assays. Development and optimization of clinical treatment regimens can be monitored by those of skill in the art by reference to the *ex vivo* and *in vivo* assays described below.

5 Ex Vivo Assay

 This system begins with *in vivo* antigen priming and measures secondary antibody responses *in vitro*. The basic protocol was documented and optimized for a range of parameters including: antigen dose for priming and time span following priming, number of cells cultured *in vitro*, antigen concentrations for eliciting secondary IgE (and other
10 Ig's) response *in vitro*, fetal bovine serum (FBS) batch that will permit optimal IgE response *in vitro*, the importance of primed CD4+ T cells and hapten-specific B cells, and specificity of the ELISA assay for IgE (Marcelletti and Katz, *Cellular Immunology* 135:471-489 (1991); incorporated herein by reference).

 The actual protocol utilized for this project was adapted for a more high
15 throughput analyses. BALB/cByj mice were immunized i.p. with 10 µg DNP-KLH adsorbed onto 4 mg alum and sacrificed after 15 days. Spleens were excised and homogenized in a tissue grinder, washed twice, and maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.0005% 2-mercaptoethanol. Spleen cell cultures were established (2-3 million cells/ml, 0.2 ml/well
20 in quadruplicate, 96-well plates) in the presence or absence of DNP-KLH (10 ng/ml). Test compounds (2 µg/ml and 50 ng/ml) were added to the spleen cell cultures containing antigen and incubated at 37° C for 8 days in an atmosphere of 10% CO₂.

 Culture supernatants were collected after 8 days and Ig's were measured by a modification of the specific isotype-selective ELISA assay described by Marcelletti and
25 Katz (*Supra*). The assay was modified to facilitate high throughput. ELISA plates were prepared by coating with DNP-KLH overnight. After blocking with bovine serum albumin (BSA), an aliquot of each culture supernatant was diluted (1:4 in phosphate buffered saline (PBS) with BSA, sodium azide and Tween 20), added to the ELISA plates, and incubated overnight in a humidified box at 4° C. IgE levels were quantitated

WO 99/61013

PCT/US99/11363

following successive incubations with biotinylated-goat antimouse IgE (b-GAME), AP-streptavidin and substrate.

Antigen-specific IgG1 was measured similarly, except that culture supernatants were diluted 200-fold and biotinylated-goat antimouse IgG1 (b-GAMG1) was substituted for b-GAME. IgG2a was measured in ELISA plates that were coated with DNP-KLH following a 1:20 dilution of culture supernatants and incubation with biotinylated-goat antimouse IgG2a (b-GAMG2a). Quantitation of each isotype was determined by comparison to a standard curve. The level of detectability of all antibody was about 200-400 pg/ml and there was less than 0.001% cross-reactivity with any other Ig isotype in the ELISA for IgE.

In Vivo Assay

Compounds found to be active in the *ex vivo* assay (above) were further tested for their activity in suppressing IgE responses *in vivo*. Mice receiving low-dose radiation prior to immunization with a carrier exhibited an enhanced IgE response to sensitization with antigen 7 days later. Administration of the test compounds immediately prior to and after antigen sensitization, measured the ability of that drug to suppress the IgE response. The levels of IgE, IgG1 and IgG2a in serum were compared.

Female BALB/cByj mice were irradiated with 250 rads 7 hours after initiation of the daily light cycle. Two hours later, the mice were immunized i.p. with 2 μ g of KLH in 4 mg alum. Two to seven consecutive days of drug injections were initiated 6 days later on either a once or twice daily basis. Typically, i.p. injections and oral gavages were administered as suspensions (150 μ l/injection) in saline with 10% ethanol and 0.25% methylcellulose. Each treatment group was composed of 5-6 mice. On the second day of drug administration, 2 μ g of DNP-KLH was administered i.p. in 4 mg alum, immediately following the morning injection of drug. Mice were bled 7-21 days following DNP-KLH challenge.

Antigen-specific IgE, IgG1 and IgG2a antibodies were measured by ELISA. Periorbital bleeds were centrifuged at 14,000 rpm for 10 min, the supernatants were diluted 5-fold in saline, and centrifuged again. Antibody concentrations of each bleed

WO 99/61013

PCT/US99/11363


were determined by ELISA of four dilutions (in triplicate) and compared to a standard curve: anti-DNP IgE (1:100 to 1:800), anti-DNP IgG2a (1:100 to 1:800), and anti-DNP IgG1 (1:1600 to 1:12800).

5 Active Compounds of the Present Invention

The following series of compounds were found to be potent inhibitors of IgE in both *ex-vivo* and *in vivo* models.

One family of small molecule IgE inhibitors in accordance with the present invention include substituted benzanilides, defined by formula I:

10




I

15

where n is 1 to 3, R is H, alkyl, aryl, aminoalkyl, alkylaminoalkyl, substituted aryl or hydroxyalkyl, and where X, Y and Z are selected independently from the group consisting of H, alkoxy, aryloxy, alkyl, aryl, heteroaryl, hydroxyalkyl, carboxy, amine, alkylamino, cycloalkylamine, morpholine, thiomorpholine, alkoxycarbonyl, hydroxy, cyano, sulfonamide, alkylsulfonamide, substituted aryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, nitro, halogen, thioalkyl, sulfoxyalkyl, sulfonylalkyl or the like.

20

One compound encompassed within the definition of formula I, which was active in suppressing IgE, is represented by formula I.1:




WO 99/61013

PCT/US99/11363

I.1


Compounds of formula I can be synthesized by the following reaction:



5

The reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog numbers T6,980-9 and 19,323-2. Modifications as suggested by formula I can be prepared by conventional reactions, well known in the field.

Another family of small molecule IgE inhibitors is defined by generic formula II(1) below.




II(1)

wherein X is a cycloalkyl or substituted cycloalkyl having from 4-6 carbons, where R₁ and R₂ are independently H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl, where R₃ is H, alkyl, aryl, CO-alkyl, CO-aryl, dialkylaminoalkyl, dialkylaminoalkylcarbonyl, substituted aryl, substituted heteroaryl and CO-heteroaryl, and where R is H, aryl, heteroaryl, substituted aryl, substituted heteroaryl or the like.

More preferably, the genus is represented by formula II(2).

20



II(2)


WO 99/61013

PCT/US99/11363


where X and Y are independently H, alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, aryl, benzyl, heteroaryl, hydroxy, carboxy, halogen, trifluoromethyl, trifluoromethoxy, carboxyalkyl, nitro, cyano, sulfonamide, alkylsulfonamides, amino, alkylamino, morpholine, thiomorpholine, alkylthio, sulfoxyalkyl and sulfonylalkyl, where R₁ and R₂ are independently H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl, and where R₃ is H, alkyl, aryl, CO-alkyl, CO-aryl or CO-heteroaryl.

The following compounds within the genus were synthesized and found to be active in suppressing IgE:


10




II.1



II.2




II.3




II.4

WO 99/61013

PCT/US99/11363



II.5



II.6

Compounds of formula II may be synthesized by any conventional reactions known in the art. Examples of syntheses include the following reactions:

A solution of DL- α -methyl-benzylamine (2.0 g, 0.017 mol) in MeOH (7.0 ml) and epichlorohydrine (1.53 g, 0.017 mol) in MeOH (7.0 ml) was stirred at room temperature for some time and then heated at about 45-50° C for 3 days. The reaction mixture was basified with 10% NaOH solution and then extracted with ether (2 x 25 ml), ether layer washed with brine, concentrated and distilled. The yield was 1.507 g, b.p. 116-120° C.


The stereochemistry variation was achieved by stirring a solution of R-(+)-1-phenylethylamine (2.0 g, 0.017 mol) in 7.0 ml of MeOH with epichlorohydrine (1.53 g, 0.017 mol) in MeOH (7.0 ml). The reaction was carried out as detailed above.

The reactants can be obtained from a commercial supplier, such as for example, Aldrich Chemical Company, catalog number 16,854-8. Modifications as suggested by formulas II(1-2) can be prepared by conventional reactions, well known in the field.

Substituted benzene rings with acylamide groups are also contemplated in accordance with the present invention, as described by generic formula III:

WO 99/61013


PCT/US99/11363



III

wherein X and Y are independently H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino or alkylamino, wherein R, R', R'' and R''' are independently H, alkyl, alkoxyalkyl or dialkylaminoalkyl, and where R'' and R''' may independently also be a halogen.

A preferred variation on compound III is illustrated by the formula:



III(1)

wherein Z is H₂ or O; wherein X and Y are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and alkylamino; and wherein R₁ and R₂ may be selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

The following species of formula III(1) were synthesized and found to be active in suppressing IgE (see Table 1).

Table 1


	R ₁ = R ₂	Z	X=Y
III.1	2,2-dimethyl-cyclopropyl	O	H
III.2	cyclopropyl	H ₂	H

WO 99/61013

PCT/US99/11363

III.3	cyclohexyl	O	H
III.4	2,2,3,3-tetramethyl-cyclopropyl	H ₂	H
III.5	4-methyl-benzenesulfonyl	H ₂	H
III.6	cyclobutyl	H ₂	H
III.7	2-phenyl-cyclopropyl	H ₂	H
III.8	1-phenyl-cyclopropyl	H ₂	H
III.9	2-methyl-cyclopropyl	H ₂	H
III.10	1-methyl-cyclopropyl	H ₂	H
III.11	cyclopentyl	H ₂	H
III.12	2,2-dimethyl-cyclopropyl	H ₂	Cl

The following symmetrical cyclopropyl compound within the genus was found to be particularly active in suppressing IgE:



III.1

The cyclopropyl substituted compound above was prepared in sequential reactions. First, 2,2-dimethyl-1,3-propane-ditosylate was synthesized by adding p-toluenesulfonyl chloride (1000 g, 5.25 mol) at 0° C to a solution of neopentyl glycol (218 g, 2.1 mol) in 500 ml pyridine with stirring. The mixture was stirred for 1.5 hr and then poured into 1500 ml water in a slow stream while stirring vigorously. It was stirred for an additional 1.5 hr and then filtered. The crude solid was recrystallized from acetone (2.0 L), filtered, washed with water (2 x 0.5 L), hexane (1 x 0.5 L) and dried. Snow white solid (814 g) m.p. 120-121° C.

2,2-Dimethyl-cyclopropyl nitrile was synthesized by stirring the 2,2-dimethyl-1,3-propane-ditosylate prepared above (412 g, 1.0 mol) with KCN (195.4 g, 3.0 mol) in 2.0 L of ethylene glycol with heating (E.R. Nelson et al., JACS, 1957, p. 3467). At around 80°

WO 99/61013

PCT/US99/11363

C, a clear solution was formed. The desired product began to distill out at about 175° C. The distillation was continued until the temperature reached 200° C. The distillate (300 ml) formed two layers. The upper layer was separated and the lower layer was extracted with hexane (3 x 200 ml). The combined extracts were dried over Na₂CO₃, concentrated and re-distilled at normal pressure. The yield was 41.7 g (43.8%), b.p. 151-152° C.

2,2-Dimethyl-cyclopropyl carboxylic acid was prepared by mixing 2,2-dimethyl-cyclopropyl nitrile (41.7 g, 0.43 mol) with sodium hydroxide (44 g, 1.05 mol) in water (100 ml) and methanol (50 ml). The mixture was heated to reflux for 48 hr until a clear solution formed. Methanol was distilled off and the aqueous portion was extracted with ether (50 ml) and the aqueous layer was diluted with water (500 ml) and carefully acidified with conc. HCl. The acidified mixture was extracted with ether (5 x 300 ml), CH₂Cl₂ (5 x 300 ml). The extract was evaporated to yield a liquid which was distilled to give 44.9 g (91.6%) of oil, b.p. 55-57° C at 0.3 mm.


2,2-Dimethyl-cyclopropyl carboxylic acid chloride was prepared by mixing 2,2-dimethyl-cyclopropyl carboxylic acid (20.0 g, 0.18 mol) in CH₂Cl₂ (100 ml) with 45.7 g (0.36 mol, 31.4 ml) of oxalyl chloride. The mixture was stirred for 1.0 hr and then a small amount of DMF was added to ensure the completion of the reaction. The mixture was then distilled to give 17.8 g (75%) of the desired product, b.p. 84-87° C.

Compound III.1, Bis-[4-(2',2'-dimethyl-cyclopropyl carboxy-amido phenol)]-methane, was prepared by combining a solution of 4,4'-methylenedianiline (0.67 g, 3.4 mol) and diisopropyl-ethyl-amine (1.94 g, 2.61 ml, 0.019 mol) in THF (10 ml). The mixture was treated slowly with a solution of 2,2-dimethyl-cyclopropyl carboxylic acid chloride (1.0 g, 7.5 mmol) in THF (10 ml). The reaction mixture was stirred for 1.0 hr and then decomposed with water (250 ml). The precipitated solid was filtered and washed with 10% HCl (10 ml), 10% sodium hydroxide (10 ml), water and ether. The yield was 1.2 g, m.p. 207-210° C.

Related compounds within the genus can be synthesized following the above reactions. A general synthetic scheme is outlined below:


WO 99/61013

PCT/US99/11363



The reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog number 13,245-4, and dialkylcyclopropane carboxylate is available from Sumitomo, Japan. Modifications as suggested by formulas III(1-4) can be prepared by conventional reactions, well known in the field.

A closely related genus of compounds was also found to active in down-regulating IgE levels. This class of compounds is represented by formula IV:



where Z is H_2 or O, and X and Y are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and alkylamino. R_1 and R_2 may be selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and the like.


A species wherein $\text{Z} = \text{H}_2$, $\text{X} = \text{H}$, $\text{Y} = \text{H}$ and $\text{R}_1 = \text{R}_2 = \text{dimethyl-cyclopropyl}$ was prepared from 3,6-thioxanthenediamine-10,10-dioxide (0.89 g) and 1.0 g of 2,2-dimethyl-

WO 99/61013

PCT/US99/11363

cyclopropyl carboxyl chloride (see above) in the presence of di-isopropyl-ethylamine (2.6 ml) in THF. The yield was 1.4 g, m.p. 273-275° C.


Another class of compounds which down-regulates IgE responses in accordance with the present invention is illustrated by the formula V:



V

wherein X and Y are independently H, halogens, alkyl, alkoxy, aryl, amino, alkylamino, cycloalkylamino, morpholine, thiomorpholine, hydroxy, cyano, nitro, carboxy, alkoxycarbonyl, trifluoromethyl or trifluoromethoxy, and R, R', R'' and R''' are independently alkyl, aryl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, heteroaryl, arylalkyl, dialkylaminoalkyl, hydroxyalkyl and related groups.


The following compounds encompassed within the family defined by formula V were prepared and found to be active in suppressing IgE:




V.1

WO 99/61013


PCT/US99/11363



V.2




V.3




V.4

WO 99/61013


PCT/US99/11363



V.5



V.6




V.7

WO 99/61013


PCT/US99/11363

Compounds of formula V can be synthesized by any conventional reactions known in the art. The above species V.1-7 were synthesized by the following reaction, where the benzene ring can be substituted, as indicated by the X (e.g., bromide, as in V.2) and the amide is varied to yield the desired compounds:



The reactants were obtained from commercial suppliers, such as Aldrich Chemical Company, catalog number 19,169-8. Modifications can be prepared by conventional reactions, well known in the field.

Another useful class of compounds is represented by the formula VI:




VI

where R is aliphatic, aromatic, heterocyclic, substituted aromatic, substituted heterocyclic or the like, and where X and Y are independently, H, halogen, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, cyano or the like. Replacement of the carboxylic acid with other bioisosteric groups such as tetrazole and tetrazoleamide is also contemplated in accordance with the present invention.


The following compounds encompassed within the family defined by formula VI were prepared and found to be active in suppressing IgE:

WO 99/61013


PCT/US99/11363




VI.1



VI.2






VI.3




VI.4

WO 99/61013

PCT/US99/11363



- 5 Compounds of formula VI may be synthesized by any conventional reactions known in the art. One example of a synthesis reaction is shown below:




Where the reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog numbers B460-0 and 10,080-3. Modifications can be prepared by conventional reactions, well known in the field.

10

WO 99/61013

PCT/US99/11363


Other small molecules active in suppressing IgE include those represented by formula VII.



VII

- 5 where R_1 is H, halogen, alkoxy, alkyl, nitro, cyano, amino, CF_3 , OCF_3 or hydroxy, where R_2 is H, alkyl or aminoalkyl, where R_3 is H or alkyl, and where R_4 and R_5 are independently H, alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, cycloalkyl, aminocycloalkyl, aryl, hydroxyalkyl, substituted aryl or the like.


- 10 The following compounds encompassed within the family defined by formula VII were prepared and found to be active in suppressing IgE:




VII.1

WO 99/61013


PCT/US99/11363




VII.2



VII.3




VII.4



VII.5


WO 99/61013

PCT/US99/11363




VII.6

Compounds of formula VII may be synthesized by any conventional reactions known in the art. The compounds above (VII.1-6) were prepared according to the reaction illustrated below, where X represents the different substitutions on the benzene ring:



The reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog numbers 19,374-2 and T8,380-1. Modifications can be prepared by conventional reactions, well known in the field.

Other substituted benzene ring molecules contemplated in accordance with the invention are illustrated by formula VIII(1):



VIII(1)

where R and R' are selected independently from the group consisting of H, methyl, alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, and where X, Y and


WO 99/61013

PCT/US99/11363


Z are independently H, halogen, alkyl, alkoxy, benzo, fused heterocyclic, CF_3 , OCF_3 , CN, nitro, COOH or COOR ".

Compounds encompassed by formula VIII(1) were prepared and found to be active in suppressing IgE; they are represented by formulas VIII.1 and VIII.2:

5




VIII(1).1



VIII(1).2

10

Another useful class of compounds in accordance with the present invention represents a modification of formula VIII(1), by replacement of the benzene ring with a heterocyclic ring. These compounds are represented by formula VIII(2):



VIII(2)


15

where the heterocyclic ring is pyridines, quinolines, substituted pyridines, substituted quinolines or other heterocyclic compounds, and where R and R' are independently H, methyl, alkyl, aryl or substituted aryl.

Compounds of formula VIII may be synthesized by any conventional reactions known in the art. An example of a synthesis reaction is shown below:

WO 99/61013


PCT/US99/11363



Where the reactant can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog number 12,213-0. Modifications can be prepared by conventional reactions, well known in the field.

5

Another family of compounds active in the suppressing the IgE response are represented by formula IX(1):



IX(1)


- 10 wherein X and Y are selected independently from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, halogen, NO₂, CF₃, OCF₃, NH₂, NHR₃, NR₃R₄ and CN. Z is O, S, NH, and N-R'. R is selected from the group consisting of H, alkyl, halogen, alkoxy, CF₃ and OCF₃. R' is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl, and R₁ and R₂ are
- 15 independently selected from the group consisting of H, alkyl, aminoalkyl,

WO 99/61013

PCT/US99/11363

dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl.

Several compounds (IX.1-9) encompassed within the broad family defined by formula IX(1) were prepared and found to be active in suppressing IgE. They are defined by formula IX(2) with X, R₁ and R₂ specified in Table 2:



IX(2)



10

Table 2





	R ₁	R ₂	X
IX.1	H	5-Cl	NH
IX.2	6-Cl	5-Cl	NH
IX.3	H	5-CH ₃	O
IX.4	5-SO ₂ CH ₂ CH ₃	H	O
IX.5	H	6-OCH ₃	O
IX.6	H	5-COOH	NH
IX.7	H	6-OCH ₃	O
IX.8	H	4-CH ₃	O
IX.9	H	5-CF ₃	N-CH(CH ₃) ₂

Compounds of formula IX may be synthesized by any conventional reactions known in the art. An example of a synthesis reaction is shown below:

WO 99/61013



PCT/US99/11363



The reactants can be obtained from a commercial suppliers, such as Molecular Probes Inc., catalog number D-1421 and Aldrich Chemical Company, catalog number 39,898-5. Modifications can be prepared by conventional reactions, well known in the field.


5 Another synthesis that was used successfully to produce 3-(6'-methyl-2'-benzoxazolyl)-7-diethylamino-2H-1-benzopyran-2-one ($R_1 = \text{H}$, $R_2 = 6\text{-CH}_3$ and $X = \text{O}$) involved mixing 7-diethylamino-2-oxo-2H-1benzopyran-3-carboxylic acid (2.5 g, 9.57 mol) [CIBA Ltd., British Patent 914719; Chem Abs. 61 (1964) 3242e; Ayyangar et al., Dyes & Pigments, 13:301-316 (1990)], 2-hydroxy-4-methylaniline (1.18 g, 9.57 mol) and
10 PPA (25 ml). The mixture was stirred at 180° C for 5.0 hr, then poured into ice-water (400 ml), neutralized with 10% NaOH and 10% NaHCO_3 to pH 8.5 and extracted with CHCl_3 (4 x 400 ml). The chloroform extract was dried and treated with charcoal, filtered and concentrated. The residue was recrystallized from hexane and CH_2Cl_2 (1:1) to give 1.75 g, m.p. 189-191° C.

15 A mixture of 7-diethylamino-2-oxo-2H-1benzopyran-3-carboxylic acid, the appropriate substituted o-aminophenol or o-phenylenediamine and PPA were stirred at 180° C for several hrs, as detailed above for each of the species IX.1-9.

WO 99/61013

PCT/US99/11363

Another group of compounds active in the suppressing the IgE response are represented below. In particular, substituted 1,3,5-triazine compounds are illustrated in X(1):




5

X(1)

where R_1 and R_2 are independently H, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, where X is H, halogen, alkoxy, alkyl, CF_3 , NO_2 , CN or OCF_3 , and where R_3 and R_4 are independently H, alkyl, cycloalkyl, oxacycloalkyl or thiocycloalkyl.

General modification of the 1,2,3-triazine ring, useful in the present invention is represented by formula X(2):

10



X(2)


where R_1 , R_2 , R_3 , R_4 , R_5 and R_6 are the same or different and selected independently from the group consisting of alkyl, cycloalkyl, oxacycloalkyl, thiocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, substituted aryl and substituted heteroaryl.

15

One compound encompassed by formula X was prepared and found to be active in suppressing IgE; it is represented by formula X.1:


WO 99/61013

PCT/US99/11363



X.1

Compounds of formula X may be synthesized by any conventional reactions
 5 known in the art. An example of a synthesis reaction is shown below:




The reactant can be obtained from a commercial suppliers, such as Aldrich Chemical Company, catalog number C9,550-1. Modifications can be prepared by conventional reactions.

10

WO 99/61013

PCT/US99/11363

Another group of compounds which are active in inhibiting the IgE response in the *ex vivo* and *in vivo* assays is represented by formula XI:



XI

where R_1 and R_2 are independently H, alkyl, aryl, alkylaryl, substituted alkyl, substituted arylalkyl, dialkyl and aminoalkyl, and where R_3 is H, alkyl, aryl, halogen, CF_3 , OCF_3 , CN, NO_2 , NH_2 , NHR, carboxy, carboxyalkyl, alkoxy, heteroaryl, fused aryl, fused heteroaryl and the like.

A series of compounds encompassed within the definition of formula XI were synthesized according to the following reaction, where the compounds are defined by the substitutions provided in Table 3.

To a solution of 4-(1-adamantyl)-phenol (10 g, 0.044 mol) in DMF (40 ml) at $-5^\circ C$ was added to solid sodium hydride (1.8 g, 0.077 mol) and DMF (20 ml). After the evolution of gas ceased, epichlorhydrin was added dropwise with stirring. The reaction mixture was stirred for 48 hr and then poured onto cold water (500 ml), extracted with EtOH (3 x 100 ml), dried, concentrated to give 8.1 g of the desired epoxide. Purity was measured by GC at 94.1%.

The epoxide (1.0 g) was reacted with excess tert-butylamine at $60^\circ C$ for 24 hr and worked up as described above to give 1.1 g of the desired product, m.p. $94-96^\circ C$.

Table 3

	R_1	R_2
XI.1	H	isopropyl
XI.2	H	2-(2',5'-dimethoxy)-phenylethyl

WO 99/61013


PCT/US99/11363

XI.3


 $R_1 = R_2 = \text{thiomorpholine}$

Compounds encompassed by formula XI were prepared and found to be active in suppressing IgE; they is represented by formulas XI.1-4:


5




XI.1



XI.2



XI.3




XI.4

WO 99/61013

PCT/US99/11363

Compounds of formula XI may be synthesized by any conventional reactions known in the art. The above compounds were synthesized according to the reaction illustrated below:



- 5 The reactants can be obtained from a commercial suppliers, such as Aldrich Chemical Company, catalog number 39,347-9. Modifications can be prepared by conventional reactions.

Suppression of IgE Response

- 10 The inhibitory activity of the small molecules of the present invention were assayed using both the *ex vivo* and *in vivo* assays as described above. All of the compounds presented above were active in suppressing the IgE response. In the *ex vivo* assay, compounds in genres I-XI produced 50% inhibition at concentrations ranging from 1 pM to 10 μ M. In the *in vivo* assay, the compounds were effective at concentrations
- 15 ranging from less than about 0.01 mg/kg/day to about 25 mg/kg/day, when administered in divided doses (e.g., two to four times daily) for at least two to seven consecutive days. Thus, the small molecule inhibitors of the present invention are disclosed as being useful in lowering the antigen-induced increase in IgE concentration, and consequently, in the treatment of IgE-dependent processes such as allergies in general and allergic asthma in
- 20 particular.

Treatment Regimens

The amount of the IgE inhibitor compound which may be effective in treating a particular allergy or condition will depend on the nature of the disorder, and can be

WO 99/61013

PCT/US99/11363

determined by standard clinical techniques. The precise dose to be employed in a given situation will also depend on the choice of compound and the seriousness of the condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. Appropriate dosages can be determined and adjusted by the practitioner based on dose response relationships between the patient's IgE levels as well as standard indices of pulmonary and hemodynamic changes. Moreover, those skilled in the art will appreciate that dose ranges can be determined without undue experimentation by following the protocol(s) disclosed herein for *ex vivo* and *in vivo* screening (See for example Hasegawa et al., *J. Med. Chem.* 40: 395-407 (1997) and Ohmori et al., *Int. J. Immunopharmacol.* 15:573-579 (1993); employing similar *ex vivo* and *in vivo* assays for determining dose-response relationships for IgE suppression by naphthalene derivatives; incorporated herein by reference).

Initially, suitable dosages of the compounds will generally range from about 0.001 mg to about 300 mg per kg body weight per day in divided doses, more preferably, between about 0.01 mg and 100 mg per kg body weight per day in divided doses. The compounds are preferably administered systemically as pharmaceutical formulations appropriate to such routes as oral, aerosol, intravenous, subcutaneously, or by any other route which may be effective in providing systemic dosing of the active compound. The compositions of pharmaceutical formulations are well known in the art. The treatment regimen preferably involves periodic administration. Moreover, long-term therapy may be indicated where allergic reactions appear to be triggered by continuous exposure to the allergen(s). Daily or twice daily administration has been effective in suppressing the IgE response to a single antigen challenge in animals when carried out continuously from a period of two to seven consecutive days. Thus, in a preferred embodiment, the compound is administered for at least two consecutive days at regular periodic intervals. However, the treatment regimen, including frequency of dosing and duration of treatment may be determined by the skilled practitioner, and modified as needed to provide optimal IgE down-regulation, depending on nature of the allergen, the dose, frequency, and duration of the allergen exposure, and the standard clinical indices.

WO 99/61013

PCT/US99/11363

In one embodiment of the present invention, an IgE-suppressing compound may be administered in conjunction with one or more of the other small molecule inhibitors disclosed, in order to produce optimal down-regulation of the patient's IgE response. Further, it is envisioned that one or more of the compounds of the present invention may
5 be administered in combination with other drugs already known or later discovered for treatment of the underlying cause as well as the acute symptoms of allergy or asthma. Such combination therapies envisioned within the scope of the present invention include mixing of one or more of the small molecule IgE-inhibitors together with one or more additional ingredients, known to be effective in reducing at least one symptom of the
10 disease condition. In a variation, the small molecule IgE-inhibitors herein disclosed may be administered separately from the additional drugs, but during the same course of the disease condition, wherein both the IgE-inhibitor(s) and the palliative compounds are administered in accordance with their independent effective treatment regimens.


While a number of preferred embodiments of the invention and variations thereof
15 have been described in detail, other modifications and methods of use will be readily apparent to those of skill in the art. Accordingly, it should be understood that various applications, modifications and substitutions may be made of equivalents without departing from the spirit of the invention or the scope of the claims.

WO 99/61013

PCT/US99/11363

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising any one or more of the following compounds:




(A)

wherein n is 1 to 3;

wherein R is H, alkyl, aryl, aminoalkyl, alkylaminoalkyl, substituted aryl or hydroxyalkyl; and

wherein X, Y and Z are selected independently from the group consisting of H, alkoxy, aryloxy, alkyl, aryl, heteroaryl, hydroxyalkyl, carboxy, amine, alkylamino, cycloalkylamine, morpholine, thiomorpholine, alkoxycarbonyl, hydroxy, cyano, alkylsulfonyl, sulfonamide, alkylsulfonamide, substituted aryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, nitro, halogen, thioalkyl, sulfoxyalkyl and sulfonylalkyl;



(B)


wherein R₁ and R₂ are independently selected from the group consisting of H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl;

wherein R₃ is selected from the group consisting of H, alkyl, aryl, CO-alkyl, CO-aryl, dialkylaminoalkyl, dialkylaminoalkylcarbonyl, substituted aryl, substituted heteroaryl and CO-heteroaryl; and

wherein R is selected from the group consisting of H, aryl, heteroaryl, substituted aryl and substituted heteroaryl;

WO 99/61013

PCT/US99/11363




(C)

wherein Z is H₂ or O;

wherein X and Y are independently selected from the group consisting of
 5 H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted
 heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and
 alkylamino; and

wherein R₁ and R₂ are independently selected from the group consisting of
 H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl,
 10 substituted aryl, heteroaryl, and substituted heteroaryl;



(D)


wherein Z is H₂ or O;

wherein X and Y are independently selected from the group consisting of
 15 H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted
 heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and
 alkylamino; and

wherein R₁ and R₂ are independently selected from the group consisting
 of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl,
 20 substituted aryl, heteroaryl, and substituted heteroaryl;

WO 99/61013


PCT/US99/11363



(E)

wherein X and Y are selected independently from the group consisting of H, halogens, alkyl, alkoxy, aryl, amino, alkylamino, cycloalkylamino, morpholine, thiomorpholine, hydroxy, cyano, nitro, carboxy, alkoxycarbonyl, trifluoromethyl and trifluoromethoxy; and

wherein R, R', R'' and R''' are selected independently from the group consisting of H, alkyl, aryl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, heteroaryl, arylalkyl, dialkylaminoalkyl and hydroxyalkyl;




(F)

wherein R is selected from the group consisting of aliphatic, aromatic, heterocyclic, substituted aromatic and substituted heterocyclic; and

wherein X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, nitro, trifluoromethyl, trifluoromethoxy and cyano;

WO 99/61013

PCT/US99/11363




(G)

wherein R_1 is selected from the group consisting of H, halogen, alkoxy, alkyl, nitro, cyano, amino, CF_3 , OCF_3 and hydroxy;

5 wherein R_2 is selected from the group consisting of H, alkyl and aminoalkyl;

 wherein R_3 is H or alkyl; and

 wherein R_4 and R_5 are independently selected from the group consisting
 10 of H, alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, cycloalkyl, aryl, aminocycloalkyl, hydroxyalkyl and substituted aryl;




(H)

 wherein R and R' are selected independently from the group consisting of
 15 H, methyl, alkyl, aryl and substituted aryl; and

 wherein X, Y and Z are independently selected from the group consisting
 of H, halogen, alkyl, alkoxy, benzo, fused heterocyclic, CF_3 , OCF_3 , CN, COOH and
 COOR";

WO 99/61013

PCT/US99/11363



(I)


wherein X and Y are selected independently from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy,
 5 halogen, NO₂, CF₃, OCF₃, NH₂, NHR₃, NR₃R₄ and CN;

wherein Z is selected from the group consisting of O, S, NH, and N-R';

wherein R' is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl;

wherein R is selected from the group consisting of H, alkyl, halogen,
 10 alkoxy, CF₃ and OCF₃; and

R₁ and R₂ are independently selected from the group consisting of H, alkyl, aminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl;




(J)

where R₁, R₂, R₃, R₄, R₅ and R₆ are selected independently from the group consisting of H, alkyl, cycloalkyl, oxacycloalkyl, thiocycloalkyl, aryl, arylalkyl, heteroaryl and heteroalkyl;

WO 99/61013

PCT/US99/11363




(K)

wherein R_1 and R_2 are independently selected from the group consisting of
 5 H, alkyl, aryl, alkylaryl, substituted alkyl and substituted arylalkyl; and

wherein R_3 is selected from the group consisting of H, alkyl, aryl, halogen,
 CF₃, OCF₃, CN, NO₂, NH₂, NHR, carboxy, carboxyalkyl, alkoxy, heteroaryl, fused aryl
 and fused heteroaryl.

2. The pharmaceutical composition of Claim 1, wherein the compound is
 10 from genus A.

3. The pharmaceutical composition of Claim 2, wherein the compound is:




4. The pharmaceutical composition of Claim 1, wherein the compound is
 genus B.


15 5. The pharmaceutical composition of Claim 4, wherein the compound is
 selected from the group consisting of:

WO 99/61013


PCT/US99/11363




II.1,




II.2,




II.3,



II.4,



II.5 and




II.6.

WO 99/61013

PCT/US99/11363


6. The pharmaceutical composition of Claim 1, wherein the compound is genus C.

7. The pharmaceutical composition of Claim 6, wherein the compound is:




5 8. The pharmaceutical composition of Claim 1, wherein the compound is genus E.

9. The pharmaceutical composition of Claim 8, wherein the compound is selected from the group consisting of:



V.1,




V.2,


10

WO 99/61013


PCT/US99/11363



V.3,




V.4,




V.5,

WO 99/61013


PCT/US99/11363




VI.1,



VI.2,




VI.3,




VI.4,

WO 99/61013


PCT/US99/11363



VI.5,



VI.6 and




VI.7.

5 12. The pharmaceutical composition of Claim 1, wherein the compound is genus G.


13. The pharmaceutical composition of Claim 12, wherein the compound is selected from the group consisting of:

WO 99/61013


PCT/US99/11363




VII.1,



VII.2,




VII.3,




VII.4,

WO 99/61013

PCT/US99/11363




VII.5 and




VII.6.

14. The pharmaceutical composition of Claim 1, wherein the compound is
5 genus H.

15. The pharmaceutical composition of Claim 14, wherein the compound is
selected from the group consisting of:



VIII(1).1




VIII(1).2

WO 99/61013

PCT/US99/11363

16. The pharmaceutical composition of Claim 1, wherein the compound is genus I.

17. The pharmaceutical composition of Claim 16, wherein the compound is:



5

wherein Z is selected from the group consisting of NH, O, S and N-R';

wherein R' is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl;

wherein R₁ is selected from the group consisting of H, Cl and

10 SO₂CH₂CH₃; and


wherein R₂ is selected from the group consisting of H, Cl, CH₃, OCH₃, COOH and CF₃,

18. The pharmaceutical composition of Claim 1, wherein the compound is genus J.

15 19. The pharmaceutical composition of Claim 18, wherein the compound is:



WO 99/61013

PCT/US99/11363




20. The pharmaceutical composition of Claim 1, wherein the compound is genus K.

21. The pharmaceutical composition of Claim 20, wherein the compound is:
5 selected from the group consisting of:




WO 99/61013

PCT/US99/11363



XI.3 and



XI.4.

22. The pharmaceutical composition of any one of Claims 1-21 for use in the treatment of a disease condition associated with excess IgE.

23. The pharmaceutical composition of Claim 22, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with the disease condition associated with excess IgE.

24. The pharmaceutical composition of Claim 23, wherein said at least one additional ingredient is selected from the group consisting of a short-acting β_2 -adrenergic agonist, a long-acting β_2 -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

25. Use of the pharmaceutical composition of any one of Claims 1-21 in the preparation of a medicament for treatment of a disease condition associated with excess IgE.